DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Lyfe Capital Management Limited
Lyfe Capital Management Limited
Institutional venture firmGrand Caymanlyfecapital.comSEC venture capital fund adviserone firm, 6 filing advisers
This firm files as 6 advisers on lyfecapital.com: Lyfe Capital Global Partner Limited, Lyfe Capital Investment Management (hong Kong) Limited, Lyfe Capital Investment Management (shanghai) Co., Ltd., Lyfe Capital Investment Management Limited, Lyfe U.S LLC. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.
A premier healthcare investment platform that connects healthcare champions with global markets, supply chains, and strategic partners.
venture manager, reported GAV $575M across 1 vehicles
Importance
32
moderate
Active deployment
11
low
Emerging
0
low
Completeness
63
high
Freshness
100
high
Research priority
9
low
Identity and regulatory footprint
- Headquarters
- Grand Cayman, Cayman Islandsadviserinfo.sec.gov
- Office address
- OSIRIS INTERNATIONAL CAYMAN LIMITED, SUITE #4-210, GOVERNORS SQUARE, 23 LIME TREE BAY AVENUE, Grand Cayman, KY1-1209adviserinfo.sec.gov
- Business phone
- 86 21 5220 0390adviserinfo.sec.gov
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 29, 2024
- Private funds reported
- 1 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $575Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Lyfe Capital Management Holding Limited (Shareholder), E; Shanghai Lyfe Capital Investment Consulting Partnership Enterprise (limited Partnership) (Shareholder), E
- business email
- hr@lyfecapital.comlyfecapital.compublished by the subject
- business email
- information@lyfecapital.comlyfecapital.compublished by the subject
- business email
- newlp@lyfecapital.comlyfecapital.compublished by the subject
- business phone
- 86 21 5220 0390adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
3 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech, medtech, energy, hardware, robotics, logistics, industrial
- Stages
- not stated or not yet read
- Geography
- asia, global, japan, north america, seattle, singapore, usa, worldwide
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series c 100%
Stage at first entry
series c 100%
Sectors
unknown 100%
lead rate 50%follow-on rate 0%new logos, 12 months 3
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Lyfe Capital Fund III (dragon), L.P. | Fund | unknown | Unknown | $575M Mar 29, 2024 | 42 | $0 | Sep 26, 2019 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
18 current, 1 departed
David Liu
Investor relationsDirector of Investor Relations
Alan Wang
PartnerManaging Director
Derek Yuan
PartnerPartner
Frances Chovanec
PartnerManaging Director
Jack Chen
PartnerPartner
James Zhao
PartnerFounder and Partner
JIN Zhao
PartnerShareholder · since Jul 1, 2015
Peter Lee
PartnerManaging Director
Sameer Rohatgi
PartnerPartner
William Chen
PartnerPartner
Yao Li Ho
PartnerManaging Director
Laura Lu
Platform and operationsChief Legal Officer
Roy Xu
Platform and operationsChief Financial Officer
Alvin Koh
PrincipalInvestment Principal and Senior Director, APAC Business Development
Fong Ming Koh
PrincipalPrincipal
Jing Xu
PrincipalPrincipal
Vivien Li
PrincipalDirector of Business Development
1 departed (kept with end dates)
- Zhengkun Yu · Shareholder · Jul 1, 2015 to Mar 22, 2022 Inference
Investments on record
3 edges, 3 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Level Up Digital | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Frazier Life Sciences | portfolio listing | lead | unknown | unknown | unknown | Sep 15, 2026 | Fact Portfolio company websites (about, investors, press pages) |
| Aspen Neuroscience | Series C · Series C | participant | unknown | $115M | unknown | Nov 20, 2025 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
10 relationships from shared deals, counted for the whole firm
Frazier Healthcare Partners 1 shared · one time · we led 1Revelation Partners 1 shared · one time · they led 1 · we led 1Life Sciences 1 shared · one time · we led 1Balyasny Asset Management L.P. 1 shared · one timeCormorant Asset Management 1 shared · one timeOrbiMed 1 shared · one time · they led 1Prebys Ventures 1 shared · one timeSection 32, LLC 1 shared · one timeAxon Ventures 1 shared · one timeArch Venture Partners 1 shared · one time · they led 1
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
2 dated events
- Mar 22, 2022Zhengkun Yu (Shareholder) no longer on Schedule A of Lyfe Capital Management Limited
- Nov 26, 2019Lyfe Capital Management Limited first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $575M across 1 vehicles
Evidence
33 observations from 2 sources